JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib-Reference-Cited by-同舟云学术

JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib

Published:2015-05-21 Issue:21 Volume:125 Page:3352-3353
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Pieri Lisa¹,Pancrazzi Alessandro¹,Pacilli Annalisa¹,Rabuzzi Claudia¹,Rotunno Giada¹,Fanelli Tiziana¹,Guglielmelli Paola¹,Fjerza Rajmonda¹,Paoli Chiara¹,Verstovsek Srdan²,Vannucchi Alessandro M.¹

Affiliation:

1. Laboratorio Congiunto Malattie Mieloproliferative Croniche, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy Hematology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

2. Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/21/3352/1386419/3352.pdf

Reference11 articles.

1. New mutations and pathogenesis of myeloproliferative neoplasms.;Vainchenker;Blood,2011

2. Ruxolitinib in polycythemia vera refractory to hydroxyurea.;Vannucchi;N Engl J Med

3. Reductions in JAK2 V617F allele burden with ruxolitinib treatment in Comfort-II, a phase 3 study comparing the safety and efficacy of ruxolitinib with best available therapy (BAT) [abstract].;Vannucchi;Blood,2012

4. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.;Verstovsek;Cancer,2014